Literature DB >> 32330069

HER2-Low Breast Cancer: Pathological and Clinical Landscape.

Paolo Tarantino1,2, Erika Hamilton3, Sara M Tolaney4, Javier Cortes5,6, Stefania Morganti1,2, Emanuela Ferraro1,2, Antonio Marra1,2, Giulia Viale1,2, Dario Trapani1,2, Fatima Cardoso7, Frédérique Penault-Llorca8,9, Giuseppe Viale1,2, Fabrice Andrè10, Giuseppe Curigliano1,2.   

Abstract

Entities:  

Year:  2020        PMID： 32330069     DOI： 10.1200/JCO.19.02488

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  44 in total

Review 1.  Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.

Authors:  Jason A Mouabbi; C Kent Osborne; Rachel Schiff; Mothaffar F Rimawi
Journal:  Breast Cancer Res Treat       Date:  2021-09-13       Impact factor: 4.872

2.  Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.

Authors:  Lili Chen; Yanyang Chen; Zhongpeng Xie; Jiao Luo; Yuefeng Wang; Jianwen Zhou; Leilei Huang; Hongxia Li; Linhai Wang; Pei Liu; Man Shu; Wenhui Zhang; Zunfu Ke
Journal:  Breast Cancer Res Treat       Date:  2022-07-05       Impact factor: 4.624

3.  Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.

Authors:  Yingbo Shao; Yang Yu; Zhifen Luo; Huijuan Guan; Fangyuan Zhu; Yaning He; Qi Chen; Chaojun Liu; Bing Nie; Hui Liu
Journal:  Ann Surg Oncol       Date:  2022-08-06       Impact factor: 4.339

Review 4.  [New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis].

Authors:  Carsten Denkert; Annette Lebeau; Hans Ulrich Schildhaus; Christian Jackisch; Josef Rüschoff
Journal:  Pathologie (Heidelb)       Date:  2022-10-13

5.  Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis.

Authors:  George Douganiotis; George Kesisis; Efthalia Lalla; Ippokratis Korantzis; Ioannis Boukovinas; Konstantinos Papazisis
Journal:  Cancer Diagn Progn       Date:  2022-09-03

Review 6.  Unlocking the potential of antibody-drug conjugates for cancer therapy.

Authors:  Joshua Z Drago; Shanu Modi; Sarat Chandarlapaty
Journal:  Nat Rev Clin Oncol       Date:  2021-02-08       Impact factor: 65.011

7.  FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.

Authors:  Preeti Narayan; Christy L Osgood; Harpreet Singh; Haw-Jyh Chiu; Tiffany K Ricks; Edwin Chiu Yuen Chow; Junshan Qiu; Pengfei Song; Jingyu Yu; Frances Namuswe; Maria Guiterrez-Lugo; Sherry Hou; William F Pierce; Kirsten B Goldberg; Shenghui Tang; Laleh Amiri-Kordestani; Marc R Theoret; Richard Pazdur; Julia A Beaver
Journal:  Clin Cancer Res       Date:  2021-03-22       Impact factor: 13.801

Review 8.  Triple-negative breast cancer: promising prognostic biomarkers currently in development.

Authors:  Jasmine Sukumar; Kelly Gast; Dionisia Quiroga; Maryam Lustberg; Nicole Williams
Journal:  Expert Rev Anticancer Ther       Date:  2021-02       Impact factor: 4.512

Review 9.  Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.

Authors:  E Adams; H Wildiers; P Neven; K Punie
Journal:  ESMO Open       Date:  2021-07-02

10.  Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.

Authors:  Jacob J Kennedy; Jeffrey R Whiteaker; Laura C Kennedy; Dustin E Bosch; Melissa L Lerch; Regine M Schoenherr; Lei Zhao; ChenWei Lin; Shrabanti Chowdhury; Mark R Kilgore; Kimberly H Allison; Pei Wang; Andrew N Hoofnagle; Geoffrey Stuart Baird; Amanda G Paulovich
Journal:  Clin Chem       Date:  2021-07-06       Impact factor: 12.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.